{
    "nctId": "NCT02897375",
    "briefTitle": "Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors",
    "officialTitle": "A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies",
    "overallStatus": "COMPLETED",
    "conditions": "Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 71,
    "primaryOutcomeMeasure": "Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed solid organ malignancy\n* Patients enrolled in the expansion cohort must have histologically or cytologically confirmed squamous non-small cell lung cancer (NSCLC), breast or pancreaticobiliary tract cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \u2265 20 mm (\u2265 2 cm) with conventional techniques or as \u2265 10 mm (\u2265 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam\n* Leukocytes \u2265 3,000/mL\n* Absolute neutrophil count \u2265 1,500/mL\n* Platelets \u2265 100,000/mL\n* Hemoglobin \u2265 10 g/dL\n* Total bilirubin \u2264 1.5 \u00d7 institutional upper limit of normal (except for patients with Gilbert disease)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])/ alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) \u2264 2.5 \u00d7 institutional upper limit of normal (up to 5 X upper limit of normal \\[ULN\\] for patients with liver metastasis)\n* Creatinine within normal institutional limits OR creatinine clearance \u2265 60 mL/min/1.73 m\u00b2 for patients with creatinine levels above institutional normal\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of study drug administration\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Patients who have had cytotoxic anticancer chemotherapy or immune checkpoint inhibitor within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or palliative radiation within 2 weeks (stereotactic radiation therapy \\[SRS\\] for brain metastasis within 48 hours) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\n* Patients receiving cytotoxic agent as immunomodulatory therapy for a non neoplastic indication (e.g. methotrexate for rheumatoid arthritis) and who are unable to discontinue such agents within 2 weeks prior to starting treatment\n* Oral targeted therapy within five days or five half-lives, whichever is longer, prior to initiating protocol therapy treatment\n* Patients who are receiving any other investigational agents\n* Use of strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors and inducers\n* Patients with symptomatic uncontrolled brain metastases are excluded; (patients with stable treated or asymptomatic untreated brain metastasis not requiring glucocorticoids are allowed)\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, carboplatin or cisplatin\n* Concurrent administration of strong inducers and inhibitors of CYP3A enzyme or CYP3A substrates with narrow therapeutic window\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation\n  * Symptomatic congestive heart failure (requiring hospital stay within the last 6 months)\n  * Myocardial infarction within the last 6 months\n  * Unstable angina pectoris, cardiac arrhythmia\n  * Psychiatric illness\n* Social situations or circumstances that would limit compliance with study requirements\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclib\n* Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}